Floatz logo

Monomethyl Fumarate

ALS (Amyotrophic Lateral Sclerosis)

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the ALS (Amyotrophic Lateral Sclerosis) cohort.

Asset / SponsorPhaseRating
Ciprofloxacin
NeuroSense Therapeutics Ltd.
Phase 2B
TEONANACATL
University Medical Center Groningen
Phase 2B
Peripheral Blood Mononuclear Cell
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Phase 2B
Treg Cells
The Methodist Hospital Research Institute
Phase 2B
Nerandomilast
Gipfel Life Sciences GmbH
Phase 2/3CCC

View all 15 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →